TMAO contributes to the progression of DCM through four major pathways: impairing mitochondrial function/energy metabolism, activating systemic inflammation (NF-κB, NLRP3), promoting fibrosis (Smad3), and inducing endothelial dysfunction. The gene discussed is NFKB1; the disease is endothelial dysfunction.